ACAD — ACADIA PHARMACEUTICALS INC

Ownership history in Stonepine Capital Management, LLC  ·  8 quarters on record

This page tracks every 13F SEC filing in which Stonepine Capital Management, LLC reported a position in ACADIA PHARMACEUTICALS INC (ACAD). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
4.76% (2025 Q2)
Avg. % of fund
2.12%
First filed
2018 Q2
Last filed
2025 Q4
Quarters held
8
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 100,000 -74,544 -42.7% 1.95% $2.7M $26.71
2025 Q3 REDUCED 174,544 -50,456 -22.4% 3.03% $3.72B $21.34
2025 Q2 ADDED 225,000 +131,607 +140.9% 4.76% $4.9M $21.57
2025 Q1 REDUCED 93,393 -126,607 -57.5% 0.18% $185.8M $16.61
4 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    ACAD price (monthly, adj. close)

Other funds also holding ACAD

As of 2025 Q4 — sorted by position size

Palo Alto Investors LP 3Y 7Y 9.24% BAKER BROS. ADVISORS LP 3Y 7Y 6.71% Birchview Capital, LP 3Y 7Y 2.67% Nan Fung Group Holdings Ltd 3Y 2.46% Axecap Investments, LLC 2.25% RTW INVESTMENTS, LP 3Y 7Y 1.91% BRAIDWELL LP 3Y 1.74% Logos Global Management LP 3Y 1.37% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 1.1% HUSSMAN STRATEGIC ADVISORS, INC. 3Y 7Y 0.95%
← Back to Stonepine Capital Management, LLC Holdings